Therapeutic Antibodies

#Biologics #GlobalData #Inflammatory Bowel Disease #Market reporting #Small molecules

Biologics for bowel disease face threat from cheaper small molecules

The total sales of inflammatory bowel disease (IBD) drugs are estimated to reach approximately $10.2 billion in the US in 2023, according to analysts. The increase in IBD biologic treatments has been a major driving force in the growth of this market in recent years. In 2007, AbbVie’s Humira received… Read More

#Market Reports #News

Monoclonal antibodies
#Anti-inflammatory #Financing #Lassen Therapeutics #Monoclonal antibodies #Ophthalmology

$85m fund supports monoclonal antibody for fibro-inflammatory disorders

Antibody therapeutics company Lassen Therapeutics has closed an oversubscribed $85 million Series B financing. The proceeds will fund a Phase II study in thyroid eye disease (TED) with the company’s monoclonal antibody LASN01 and the continued development of LASN500 for cancer. The clinical programme for LASN01 is focused primarily in… Read More

#Business & Investment #News

Blood cancer
#Acute Myeloid Leukaemia #Biologics #Blood cancer #CAR-T #University College London #ViroCell Biologics

UCL accelerates research of relapse in childhood blood cancer 

The University College London (UCL) has entered into a partnership with ViroCell Biologics to advance Professor Persis Amrolia’s innovative chimeric antigen receptor (CAR) T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia (ALL).   Dr Amrolia is Professor of Transplantation Immunology at the UCL Great Ormond Street Institute of… Read More

#Cancer Research #News

Follicular lymphoma
#AbbVie #Bispecific Antibodies #Clinical trials #Follicular lymphoma #Genmab

New data for relapsed/refractory follicular lymphoma treatment 

Genmab and AbbVie have announced updated data presented at ASH from the companies’ ongoing Phase I/II EPCORE NHL-1 clinical trial investigating epcoritamab (DuoBody CD3xCD20).   Epcoritamab is a T-cell engaging bispecific antibody administered subcutaneously in 128 adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma… Read More

#News

Antibodies
#Antibodies #Antibody discovery workflow #Antibody drug conjugate (ADC) #CAR-T #Therapeutic Antibodies

Fortis Life Sciences leads the way in custom antibody discovery

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools. Fortis Life Sciences offers… Read More

#News

Natural killer cells
#Bispecific Antibodies #Cell therapy #Collaboration #NAYA Biosciences #Oncology #ONK Therapeutics

Partners explore NK cell therapy and bispecific antibodies combo

ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. The partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted… Read More

#Business & Investment #Cancer Research #News

Antibodies
#Guide #Human disease models #Mouse models #Pharmokinetics #Therapeutic Antibodies

Guide: Assessing preclinical PK in therapeutic antibodies

A new Guide is now available from The Jackson Laboratory (JAX) entitled ‘HuPK: A Humanised Platform for therapeutic antibody PK evaluation’. Download the Guide to learn more about:   How JAX’s HuPK™ Humanised FcRn Platform offers a validated and… Read More

#News

PEGS Europe posters
#Antibodies #Antibody discovery workflow #Biologics #Drug discovery #Events #PEGS Europe 2023 #Protein engineering

Reflecting on PEGS Europe 2023 

DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. Here, she shares insight from the annual biologics technology meeting.   Scientific tracks and presentations  Antibody-based cancer therapies   The first presentation attended in the antibody-based cancer therapies track, within the antibody drug… Read More

#Exclusive Content

The microbiome
#Alzheimer's #Antibodies #Cancer #Covid-19 #Rare disease #Therapeutic Antibodies

Which diseases will benefit from therapeutic antibody development?

Listen to this article on the DDW Podcast: DDW’s Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies. Cancer Monoclonal antibodies (mAbs) are a type of targeted drug therapy, and as such are often used to treat cancer. Alongside surgery, radiation and chemotherapy, antibody-based immunotherapy… Read More

#Exclusive Content

Lisbon skyline
#Bispecific Antibodies #Immunotherapy #Machine learning #PEGS Europe 2023 #Protein engineering

What to expect from PEGS Europe 2023: Day 3

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against… Read More

#Exclusive Content

Therapeutic antibodies
#Antibodies #Engineered antibodies #Immunology #Janssen #Monoclonal antibodies

Finding the North Star of therapeutic antibodies

Listen to this article on the DDW Podcast: Katie Abouzahr is the Vice President, Autoantibody Portfolio and Maternal Fetal Disease Area Leader at the Janssen Pharmaceutical Companies of Johnson & Johnson. She speaks with Megan Thomas about the future for Janssen’s investigational medicine nipocalimab and antibody therapeutics at large. A day in… Read More

#Exclusive Content

#Antibodies #Career #From the top #Interview #Women in STEM

From the Top: Adele Hannigan, Antibody Analytics

Listen to this article on the DDW Podcast: Megan Thomas shines a spotlight on Adele Hannigan, CBO for Antibody Analytics. She outlines how her interest in immunotherapy began and what keeps it alive today. MT: What has you career path looked like? Were there any key moments or milestones that led… Read More

#Exclusive Content

#Biologics #Biology #Dewpoint Therapeutics #Partnership

Podcast: In conversation with Isaac Klein, CSO, Dewpoint Therapeutics

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Isaac Klein, Chief… Read More

#News

Lisbon skyline
#Antibodies #Antibody drug conjugate (ADC) #Biochemistry #Biologics #Biologics / Biotechnology #Bispecific Antibodies #Combination therapy #Engineered antibodies #PEGS Europe 2023

What to expect from PEGS Europe 2023: Day 1

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 1, Tuesday 14 November 2023, the tracks include: Display of biologics, antibody-based cancer therapies, safety and efficacy of bispecific… Read More

#Exclusive Content

Antibodies
#AI / data analytics / healthtech / informatics #Antibodies #Antibody-based therapeutics #Artificial intelligence (AI) #Start-ups

Advancing antibody discovery with AI

Listen to this article on the DDW Podcast: DenovAI is the second start-up to launch from the global pharma consortium AION Labs -  an organisation that aims to improve the drug discovery and development process through the use of AI and other computational technologies. DDW Editor Reece Armstrong, speaks to Kashif… Read More

#Exclusive Content #Start-up Zone

Blood cancer
#Bispecific Antibodies #Cancer research #Haematology #MHRA #Oncology #UK

New UK therapy option for hard-to-treat lymphoma

The MHRA has granted conditional marketing authorisation for Tepkinly (epcoritamab) as a bispecific treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The conditional marketing authorisation for Great Britain is based on the single-arm Phase I/II EPCORE NHL-1 trial… Read More

#News #Regulatory